Tumour lysis syndrome (Cairo-Bishop criteria) represents a critical, life-threatening oncological emergency characterized by the massive, abrupt breakdown of malignant cells and the subsequent release of intracellular contents into the systemic circulation2,5. This metabolic cascade outpaces homeostatic mechanisms, resulting in hallmark biochemical derangements including hyperuricaemia, hyperkalaemia, hyperphosphataemia, and secondary hypocalcaemia2,3. These profound metabolic imbalances place patients at substantial risk for acute kidney injury (AKI), life-threatening cardiac arrhythmias, neuromuscular instability, and multiorgan system failure2,4. Although TLS can occur spontaneously prior to any intervention, it most frequently precipitates shortly after the initiation of cytotoxic chemotherapy, corticosteroids, radiotherapy, or targeted monoclonal antibody therapy in tumours characterized by high proliferative rates and extensive bulk3,5. Early identification of patient-specific risk factors, vigilant clinical monitoring, and prompt institution of targeted prophylaxis remain paramount to mitigating morbidity and mortality3,7.

1. Etiology & Risk Factors

  • High-Risk Malignancies: Burkitt lymphoma, acute lymphoblastic leukaemia (ALL) with high white blood cell counts, diffuse large B-cell lymphoma (DLBCL), and other rapidly proliferating haematological neoplasms3,4.
  • Solid Tumours: Less commonly observed in solid tumours, but significant risk occurs with bulky chemosensitive tumours such as small cell lung carcinoma, germ cell tumours, and metastatic neuroblastoma following initial cytoreductive therapy5.
  • Tumour Burden: High tumour burden, historically defined as a mass greater than or equal to 500 g or a body surface area tumour mass calculation exceeding 300 g/m2, or extensive bone marrow infiltration2.
  • Baseline Renal Impairment: Pre-existing chronic kidney disease, baseline hyperuricaemia, or structural urological obstruction that impairs the clearance of uric acid and phosphate loads4,7.
  • Spontaneous TLS: Can develop prior to any cytotoxic therapy in patients with ultra-high proliferation rates, massive tumour burden, or intrinsic renal compromise2,5.
  • Exogenous Factors: Concomitant administration of nephrotoxic medications, dehydration, or use of agents that impair renal tubular organic anion transport systems3,4.

2. Pathophysiology

The pathophysiology of tumour lysis syndrome is rooted in the overwhelming release of intracellular components from rapidly destroyed malignant cells3,5. Nucleic acids released from lysed cells are catabolized via xanthine oxidase into hypoxanthine, xanthine, and ultimately insoluble uric acid. Excessive uric acid production exceeds the renal tubular excretory capacity, leading to supersaturation in the distal renal tubules, crystal precipitation, and intrarenal obstruction. Simultaneously, massive intracellular stores of potassium are dumped into the extracellular fluid space, overwhelming the sodium-potassium adenosine triphosphatase ($Na^+/K^+$-ATPase) pumps and leading to severe hyperkalaemia. Intracellular organic and inorganic phosphates are liberated in quantities that exceed renal excretion, causing profound hyperphosphataemia. This excess circulating phosphate avidly binds ionized calcium, precipitating calcium phosphate crystals in soft tissues and the renal parenchyma, which directly drives secondary hypocalcaemia. The convergence of intrarenal crystal deposition, direct tubular toxicity from uric acid and calcium phosphate, and renal vasoconstriction culminates in rapid-onset acute kidney injury, further compounding the systemic electrolyte toxicity2,3,5.

Tumour lysis syndrome (Cairo-Bishop criteria) — Pathophysiological Cascade & Clinical Flowchart 1 Trigger / Primary Insult Initiation of cytotoxic therapy or spontaneous rapid tumour proliferation 2 Cellular / Pathophysiological Cascade Massive lysis of malignant cells releasing intracellular nucleic acids, potassium, and phosphorus 3 Target Organ / Structural Change Precipitation of uric acid and calcium phosphate crystals within renal tubules 4 Hallmark Clinical & Diagnostic Manifestation Laboratory abnormalities including hyperkalaemia, hyperphosphataemia, hypocalcaemia, and hyperuricaemia 5 Complications if Untreated & Therapeutic Target Progression to fatal cardiac arrhythmias, seizures, and multiorgan failure averted via rasburicase and hydration

3. Clinical Presentation & Classic Clinical Signs

  • History & Cardinal Symptoms: Patients frequently report vague prodromal symptoms within 12 to 72 hours of initiating cytotoxic therapy, including lethargy, nausea, vomiting, diarrhoea, anorexia, and generalized malaise. Neuromuscular symptoms such as muscle cramps, tetany, paraesthesias, and generalized weakness frequently signal severe electrolyte shifts2,4.
  • Physical Examination & Named Clinical Signs: Examination may reveal oliguria or anuria indicative of acute kidney injury. Cardiovascular evaluation can uncover irregular heart rhythms, bradycardia, or signs of haemodynamic instability due to severe hyperkalaemia or hypocalcaemia. Neuromuscular testing may elicit positive Chvostek or Trousseau signs secondary to marked hypocalcaemia, alongside hyperactive deep tendon reflexes or diminished reflexes depending on the exact balance of potassium and calcium derangements4,7.

4. Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Diagnostic Modality / Test Expected Clinical & Radiological / Laboratory Finding
Gold-Standard InvestigationCairo-Bishop Diagnostic Criteria requiring simultaneous documentation of two or more specific metabolic abnormalities within a specified temporal window (3 days prior to to 7 days after starting cytotoxic therapy).
Laboratory PanelSerum uric acid greater than or equal to 8 mg/dL (476 umol/L) or a 25 percent increase from baseline; serum potassium greater than or equal to 6.0 mmol/L or a 25 percent increase; serum phosphorus greater than or equal to 4.5 mg/dL (1.45 mmol/L) in adults (or greater than 6.5 mg/dL in children) or a 25 percent increase; serum calcium less than 7.0 mg/dL (1.75 mmol/L) or a 25 percent decrease from baseline.
Imaging / Radiology (X-ray, US, CT, MRI)Renal ultrasonography demonstrates bilateral nephromegaly with increased renal cortical echogenicity and loss of corticomedullary differentiation, while ruling out obstructive uropathy. Chest radiography evaluates for pulmonary congestion or secondary fluid overload.
ECG / Histopathology / ProceduralElectrocardiogram reveals peaked T waves, shortened QT intervals, widened QRS complexes, prolonged PR intervals, and sinusoidal waveforms in severe hyperkalaemia, alongside QT prolongation in hypocalcaemia. Histopathology of renal biopsy (if performed) shows extensive tubular lumen plugging with uric acid and calcium phosphate crystals.

5. Staging, Classification & Clinical Scoring Systems

Criterion / Stage / Score Component Clinical Threshold, Points & Management Implication
Laboratory Tumour Lysis Syndrome (LTLS)Presence of two or more metabolic abnormalities (uric acid, potassium, phosphorus, calcium) occurring within 3 days before or 7 days after the initiation of cytotoxic therapy, meeting specific numerical thresholds without mandatory clinical sequelae. Mandates intensive monitoring and prophylactic intervention.
Clinical Tumour Lysis Syndrome (CTLS)Presence of Laboratory TLS plus one or more clinical complications attributable to metabolic derangements, including acute kidney injury (creatinine level greater than 1.5 times upper limit of normal), cardiac arrhythmias, sudden death, or neurological seizures. Requires immediate escalation to inpatient intensive care and active treatment.
Cairo-Bishop Risk Stratification: Low RiskIndicated for malignancies with low proliferation rates and minimal tumour burden (e.g., early-stage indolent non-Hodgkin lymphoma, chronic lymphocytic leukaemia with low burden). Requires standard monitoring and hydration without advanced prophylactic urate oxidase therapy.
Cairo-Bishop Risk Stratification: Intermediate RiskIndicated for intermediate proliferation and burden malignancies (e.g., high-grade non-Hodgkin lymphoma, acute myeloid leukaemia with low blast counts). Requires aggressive hydration and prophylactic allopurinol or consideration of rasburicase based on baseline renal function.
Cairo-Bishop Risk Stratification: High RiskIndicated for highly proliferative, bulky malignancies (e.g., Burkitt lymphoma, ALL with white blood cell counts greater than 100 x 109/L, or extremely elevated LDH). Demands mandatory prophylactic administration of single-dose or multi-day rasburicase alongside intensive intravenous hydration.

6. Differential Diagnosis

Differential Condition Distinguishing Clinical, Biochemical & Imaging Features
Acute Tubular Necrosis (ATN)Presents with oliguric acute kidney injury due to sepsis, ischaemia, or nephrotoxins; lacks the simultaneous constellation of massive hyperuricaemia, hyperkalaemia, and hyperphosphataemia characteristic of TLS.
Chronic Kidney Disease (CKD) ExacerbationDemonstrates baseline structural renal abnormalities on imaging, chronically elevated baseline serum creatinine, and stable or slowly progressive azotaemia rather than the rapid, massive biochemical surges seen in TLS.
RhabdomyolysisFeatures marked elevations in serum creatine kinase (CK) and myoglobinuria resulting from skeletal muscle injury, frequently associated with hyperkalaemia and hyperphosphataemia, but lacks the extreme uric acid and nucleic acid burdens driven by tumour cell lysis.
Paraneoplastic HypercalcaemiaCharacterized by elevated serum calcium levels driven by parathyroid hormone-related protein (PTHrP) or bone resorption, contrasting sharply with the profound hypocalcaemia and hyperphosphataemia of TLS.

7. Management & Treatment Protocol

  • Initial Stabilization & Resuscitation: Immediately discontinue all nephrotoxic agents, potassium supplements, and phosphate binders. Secure large-bore intravenous access and institute continuous cardiac telemetry for any patient meeting laboratory or clinical TLS criteria3,5.
  • First-Line Medical / Pharmacological Therapy (with exact adult dosing):
    • Hydration: Administer vigorous intravenous hydration with isotonic crystalloids (e.g., 0.9% normal saline or half-normal saline without potassium) at a rate of 2,000 to 3,000 mL/m2/day to maintain a target urine output of greater than 100 mL/m2/hour in adults (or 2 mL/kg/hour in children). Loop diuretics (e.g., furosemide 20 to 40 mg IV) may be added only if fluid overload occurs and euvolemia is restored after initial hydration failure to maintain brisk urine flow.
    • Urate-Lowering Agents: Rasburicase is the preferred first-line agent for high-risk patients or established hyperuricaemia, administered as a single fixed or weight-based intravenous dose of 0.2 mg/kg (maximum single dose typically 6 mg) infused in 50 mL of normal saline over 30 minutes. Allopurinol may be used for low-to-intermediate risk prophylaxis at a dose of 100 mg orally every 8 hours (maximum 800 mg/day), noting that allopurinol blocks new uric acid formation but does not reduce pre-existing uric acid levels.
    • Electrolyte Management: Treat severe hyperkalaemia aggressively with intravenous regular insulin (10 units IV with 50 mL of 50% dextrose) and calcium gluconate (1 to 2 g IV over 5 minutes strictly reserved for ECG changes or severe arrhythmias), alongside sodium polystyrene sulfonate or gastrointestinal potassium binders. Manage profound symptomatic hypocalcaemia judiciously with intravenous calcium salts only when life-threatening neuromuscular instability or arrhythmias arise.
  • Surgical / Interventional Indications: Urgent renal replacement therapy, such as continuous renal replacement therapy (CRRT) or haemodialysis, is indicated in patients with refractory hyperkalaemia, severe oliguric or anuric acute kidney injury, refractory fluid overload, severe hyperphosphataemia with symptomatic hypocalcaemia, or unresponsiveness to medical management2,5.

8. Complications & Prognosis

  • Complications: Major acute complications include severe acute kidney injury requiring temporary or permanent dialysis, lethal ventricular arrhythmias (ventricular tachycardia or ventricular fibrillation) driven by extreme hyperkalaemia, generalized tonic-clonic seizures from profound metabolic disarray, and multiorgan system failure2,4.
  • Prognosis: Prognosis depends heavily on timely recognition, baseline renal function, and early initiation of risk-adapted prophylaxis. While laboratory TLS carries a manageable clinical trajectory when treated proactively, clinical TLS complicated by oliguric renal failure or refractory arrhythmias historically carries a significantly elevated inpatient morbidity and mortality rate3,7.